Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use
نویسندگان
چکیده
منابع مشابه
Plerixafor use for peripheral blood stem cell mobilization in Korea
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Hematologic Malignancy Branch, National Cancer Center, Ilsan, Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea...
متن کاملPlerixafor for autologous CD34+ cell mobilization
High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis b...
متن کاملPlerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria.
To the Editor: Autologous progenitor cell transplantation (APCT) after a high dose of conditioning chemotherapy is now an established treatment modality for many hematological malignancies. Clinical results and survival after APCT depend on disease chemosensitivity at transplant, efficacy of the conditioning regimen, and quantity of CD34 cells infused. Most autologous progenitor cell mobilizati...
متن کاملEconomic evaluation of plerixafor for stem cell mobilization.
INTRODUCTION Autologous peripheral stem cell transplantation (ASCT) with high-dose chemotherapy is a preferred treatment for relapsed non- Hodgkin lymphoma (NHL) patients. Estimated failure rates with current stem cell mobilization (SCM) regimens are 5% to 30%. Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G P) is superior to G-CSF alone for SCM in heavily pretreated NHL patien...
متن کاملPlerixafor
Author's disclosures of potential conflicts of interest are found at the end of this article. S ince the early 1980s, high-dose chemotherapy followed by autologous hematopoi-etic stem cell transplantation (HSCT) has emerged as standard therapy for patients with hematologic ma-lignancies, including non-Hodgkin lymphoma (NHL) and multiple myelo-ma (MM). In 2009, 32,000 autologous transplants were...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cytotherapy
سال: 2015
ISSN: 1465-3249
DOI: 10.1016/j.jcyt.2015.09.002